Drugs: fezolinetant
FDA Approves Veozah: New Non-Hormonal Menopause Treatment
Veozah, recently approved by the FDA, provides a non-hormonal option for managing menopause symptoms, marking a significant advancement in women's health.
Executive Summary
- Veozah, recently approved by the FDA, provides a non-hormonal option for managing menopause symptoms, marking a significant advancement in women's health.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 04, 2026
The U.S. Food and Drug Administration (FDA) has granted FDA Veozah approval for fezolinetant (Veozah), a novel non-hormonal therapy, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. This approval marks a significant advancement by providing an alternative for patients seeking non-hormonal options to manage their symptoms.
Drug Overview
Fezolinetant (Veozah) is a selective neurokinin 3 receptor (NK3R) antagonist. It is specifically indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The drug's non-hormonal mechanism of action offers a distinct advantage, addressing safety concerns associated with traditional hormone replacement therapy.
Clinical Insights
The FDA approval of fezolinetant (Veozah) was based on the review of Phase 3 clinical trial data. [Source: U.S. Food and Drug Administration] These trials demonstrated a significant reduction in the frequency and severity of hot flashes compared to placebo. Common adverse events reported in the clinical trials include headache, nausea, and fatigue. The trials also indicated a favorable safety profile, with no significant hormonal side effects observed.
Regulatory Context
The FDA approval followed a review of clinical trial data supporting the efficacy and safety of fezolinetant (Veozah). The approval process generally involves preclinical studies, Phase 1 safety trials, Phase 2 dose-finding studies, and pivotal Phase 3 efficacy and safety trials. Liver function monitoring may be recommended based on clinical trial observations.
Market Impact
Fezolinetant (Veozah) enters a market where current treatment options include hormone replacement therapies, gabapentin, and selective serotonin reuptake inhibitors. It offers an alternative for menopausal women experiencing moderate to severe vasomotor symptoms who are either contraindicated for or prefer to avoid hormone therapy. There is a significant unmet need for safe, effective non-hormonal treatment options in menopausal vasomotor symptoms, positioning Veozah (fezolinetant) to potentially capture a substantial portion of the market.
Future Outlook
Future developments for fezolinetant (Veozah) may include exploring label expansions and potential combination trials. The competitive landscape will continue to evolve as other companies pursue treatments for menopause-related symptoms.
Frequently Asked Questions
What is Veozah (fezolinetant) used for?
Veozah (fezolinetant) is used to treat moderate to severe vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause.
How does Veozah (fezolinetant) work?
Veozah (fezolinetant) works by antagonizing the neurokinin 3 receptor in the hypothalamus, which helps to modulate the thermoregulatory center implicated in menopausal hot flashes.
What are the common side effects of Veozah (fezolinetant)?
Common side effects reported in clinical trials include headache, nausea, and fatigue.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-04.
